Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation

By F. Marty, P. Ljungman, R. Chemaly, J. Maertens, S. Dadwal, R. Duarte, S. Haider, A. Ullmann, Y. Katayama, Janice M. Y. Brown and 13 more. New England Journal of Medicine, 2017

1,032 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Immunology

View Paper: https://www.semanticscholar.org/paper/275eac55a394a175b8ff9aa56e40873fd2c49258

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Zareian
2. Colette Smith
3. Gabriel Wallis
4. G. Smit
5. F. Farzaneh
6. C. Caruso
7. A. Aiello
8. Mohamed Zuhair

Citations in the corpus

• Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis (2019, background): “A recent randomized controlled trial showed that stem cell transplant patients given prophylaxis with letermovir had improved survival compared to recipients of placebo, so supporting CMV as an underlying contributor to all‐cause mortality.(10) Indirect effects may also be seen in people living with”
• Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019, background): “In patients undergoing hematopoietic stem cell transplantation, Letermovir daily prophylaxis is effective in preventing clinically significant HCMV infection when used through day 100 after transplantation, with onlymild toxic effects and with lower all-cause mortality than placebo (223).”